{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:49:47Z","timestamp":1791391787653,"version":"4.3.3"},"reference-count":215,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Ouronyx Clinic"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Aesth Plast Surg"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00266-026-06141-2","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:35:49Z","timestamp":1783690549000},"page":"7784-7807","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Botulinum Toxin A Myths, Evidence, and Global Media Narratives"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8226-8534","authenticated-orcid":false,"given":"Karim","family":"Sayed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Nicoloso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efthyvoulos","family":"Sokratous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Shahsavari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"6141_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/164_2019_271","volume-title":"Handbook of experimental pharmacology","author":"SM Whitcup","year":"2021","unstructured":"Whitcup SM. The history of botulinum toxins in medicine: a thousand year journey. In: Handbook of experimental pharmacology. Cham: Springer International Publishing; 2021. p. 3\u201310. https:\/\/doi.org\/10.1007\/164_2019_271."},{"issue":"1","key":"6141_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1076\/jhin.8.1.43.1774","volume":"8","author":"PP Devriese","year":"1999","unstructured":"Devriese PP. On the discovery of Clostridium botulinum. J Hist Neurosci. 1999;8(1):43\u201350. https:\/\/doi.org\/10.1076\/jhin.8.1.43.1774.","journal-title":"J Hist Neurosci"},{"issue":"6","key":"6141_CR3","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1097\/00002508-200211001-00002","volume":"18","author":"PE Setler","year":"2002","unstructured":"Setler PE, Riley T. Therapeutic use of botulinum toxins: background and history. Clin J Pain. 2002;18(6):S119\u201324. https:\/\/doi.org\/10.1097\/00002508-200211001-00002.","journal-title":"Clin J Pain"},{"key":"6141_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2013.02.014","author":"L Simpson","year":"2013","unstructured":"Simpson L. The life history of a botulinum toxin molecule. Toxicon. 2013. https:\/\/doi.org\/10.1016\/j.toxicon.2013.02.014.","journal-title":"Toxicon"},{"key":"6141_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00702-015-1478-1","volume":"3","author":"D Dressler","year":"2016","unstructured":"Dressler D. Botulinum toxin drugs: brief history and outlook. J Neural Transm. 2016;3:123. https:\/\/doi.org\/10.1007\/s00702-015-1478-1.","journal-title":"J Neural Transm"},{"key":"6141_CR6","unstructured":"Fox-Skelly. Jasmin, Are there long-term health risks to using botox? BBC. 2024:1\u20135."},{"issue":"1","key":"6141_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00204-018-2290-0","volume":"93","author":"E Nepovimova","year":"2019","unstructured":"Nepovimova E, Kuca K. The history of poisoning: from ancient times until modern ERA. Arch Toxicol. 2019;93(1):11\u201324. https:\/\/doi.org\/10.1007\/s00204-018-2290-0.","journal-title":"Arch Toxicol"},{"key":"6141_CR8","unstructured":"Wexler P. Toxicology in the middle ages and renaissance. Academic Press; 2017."},{"issue":"1","key":"6141_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/0272-4332.00001","volume":"20","author":"L Sj\u00f6berg","year":"2000","unstructured":"Sj\u00f6berg L. Factors in risk perception. Risk Anal. 2000;20(1):91. https:\/\/doi.org\/10.1111\/0272-4332.00001.","journal-title":"Risk Anal"},{"key":"6141_CR10","unstructured":"Campbell D. Botox leads to bad reactions for one in six users, says study. Guard. 2021; 1\u20133."},{"key":"6141_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s00266-020-02027-z","author":"S Ahsanuddin","year":"2021","unstructured":"Ahsanuddin S, Roy S, Nasser W, Povolotskiy R, Paskhover B. Adverse events associated with Botox as reported in a food and drug administration database. Aesthet Plast Surg. 2021. https:\/\/doi.org\/10.1007\/s00266-020-02027-z.","journal-title":"Aesthet Plast Surg"},{"issue":"1","key":"6141_CR12","doi-asserted-by":"publisher","first-page":"116","DOI":"10.29252\/wjps.8.1.116","volume":"8","author":"A Rouientan","year":"2019","unstructured":"Rouientan A, Alizadeh Otaghvar H, Mahmoudvand H, Tizmaghz A. Rare complication of Botox injection: a case report. World J Plast Surg. 2019;8(1):116.","journal-title":"World J Plast Surg"},{"issue":"14","key":"6141_CR13","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1523\/JNEUROSCI.0375-08.2008","volume":"28","author":"F Antonucci","year":"2008","unstructured":"Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M. Long-distance retrograde effects of botulinum neurotoxin A\u201d. J Neurosci. 2008;28(14):3689\u201396. https:\/\/doi.org\/10.1523\/JNEUROSCI.0375-08.2008.","journal-title":"J Neurosci"},{"key":"6141_CR14","unstructured":"Brooke T. My Botox doesn\u2019t work like it used to, Allure, London. 2024; 1\u20132."},{"key":"6141_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s00266-025-05007-3","author":"E Rahman","year":"2025","unstructured":"Rahman E, Rao P, Sayed K, Garcia PE, Ioannidis S, Yu N, et al. Decades of scientific data and global media reporting on complications in non-surgical aesthetic treatments for a transparent safety profile: kissing snow white awake. Aesthet Plast Surg. 2025. https:\/\/doi.org\/10.1007\/s00266-025-05007-3.","journal-title":"Aesthet Plast Surg"},{"key":"6141_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00266-024-04109-8","author":"E Rahman","year":"2024","unstructured":"Rahman E, Webb WR, Rao P, Yu N, Garcia PE, Ioannidis S, et al. Generational Exploration on aesthetic medicine products: influence of social media, reviews, and brand identity\u2014GEMS bond survey. Aesthet Plast Surg. 2024. https:\/\/doi.org\/10.1007\/s00266-024-04109-8.","journal-title":"Aesthet Plast Surg"},{"key":"6141_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s00266-024-04330-5","author":"E Rahman","year":"2024","unstructured":"Rahman E, Rao P, Webb WR, Garcia PE, Ioannidis S, Tam E, et al. Integrating psychological insights into aesthetic medicine: a cross-generational analysis of patient archetypes (impact study). Aesthet Plast Surg. 2024. https:\/\/doi.org\/10.1007\/s00266-024-04330-5.","journal-title":"Aesthet Plast Surg"},{"key":"6141_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00266-024-04455-7","author":"E Rahman","year":"2024","unstructured":"Rahman E, Carruthers JDA, Rao P, Rahman Z, Esfahlani SS, Webb WR. From posts to perceptions: sentiment and psychological analysis of aesthetic enhancements on social media. Aesthet Plast Surg. 2024. https:\/\/doi.org\/10.1007\/s00266-024-04455-7.","journal-title":"Aesthet Plast Surg"},{"key":"6141_CR19","unstructured":"Masse-Joliocoeur M. An introduction to punctuated equilibrium: a model for understanding stability and dramatic change in public policies. National Collaborating Centre for Healthy Public Policy. 2018."},{"issue":"2","key":"6141_CR20","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s11077-022-09458-2","volume":"55","author":"TM Yildirim","year":"2022","unstructured":"Yildirim TM. Stability and change in the public\u2019s policy agenda: a punctuated equilibrium approach. Policy Sci. 2022;55(2):337\u201350. https:\/\/doi.org\/10.1007\/s11077-022-09458-2.","journal-title":"Policy Sci"},{"key":"6141_CR21","doi-asserted-by":"crossref","unstructured":"Devlin J, Chang MW, Lee K, Toutanova K. BERT: pre-training of deep bidirectional transformers for language understanding. 2019.","DOI":"10.18653\/v1\/N19-1423"},{"key":"6141_CR22","doi-asserted-by":"publisher","DOI":"10.21105\/joss.00861","author":"L McInnes","year":"2018","unstructured":"McInnes L, Healy J, Saul N, Gro\u00dfberger L. UMAP: uniform manifold approximation and projection. J Open Sour Softw. 2018. https:\/\/doi.org\/10.21105\/joss.00861.","journal-title":"J Open Sour Softw"},{"issue":"11","key":"6141_CR23","doi-asserted-by":"publisher","first-page":"207","DOI":"10.21105\/joss.00205","volume":"2","author":"L McInnes","year":"2017","unstructured":"McInnes L, Healy J, Astels S. Hdbscan: hierarchical density based clustering. J Open Sour Softw. 2017;2(11):207. https:\/\/doi.org\/10.21105\/joss.00205.","journal-title":"J Open Sour Softw"},{"issue":"1","key":"6141_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/jocd.12529","volume":"18","author":"E Karbassi","year":"2019","unstructured":"Karbassi E, Nakhaee N, Zamanian M. The efficacy and complications of a new technique of Abobotulinum-Toxin A (dysport) injection in patients with Glabellar Lines. J Cosmet Dermatol. 2019;18(1):55\u20138. https:\/\/doi.org\/10.1111\/jocd.12529.","journal-title":"J Cosmet Dermatol"},{"key":"6141_CR25","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1093\/asj\/sjx010","volume":"37","author":"JL Cohen","year":"2017","unstructured":"Cohen JL, Scuderi N. Safety and patient satisfaction of AbobotulinumtoxinA for aesthetic use: a systematic review. Aesthet Surg J. 2017;37:S32\u201344. https:\/\/doi.org\/10.1093\/asj\/sjx010.","journal-title":"Aesthet Surg J"},{"key":"6141_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000002013","author":"GD Monheit","year":"2020","unstructured":"Monheit GD, Baumann L, Maas C, Rand R, Down R. Efficacy, safety, and subject satisfaction after AbobotulinumtoxinA treatment for moderate to severe glabellar lines. Dermatol Surg Off Publ Am Soc Dermatol Surg. 2020. https:\/\/doi.org\/10.1097\/DSS.0000000000002013.","journal-title":"Dermatol Surg Off Publ Am Soc Dermatol Surg"},{"issue":"4","key":"6141_CR27","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s13555-020-00414-7","volume":"10","author":"R Wanitphakdeedecha","year":"2020","unstructured":"Wanitphakdeedecha R, Yan C, Apinuntham C, Rojanavanich V, Cembrano KAG, Eimpunth S, et al. Intradermal micro-dosing of AbobotulinumtoxinA for face-lifting: How long does it last? Dermatol Ther. 2020;10(4):779\u201389. https:\/\/doi.org\/10.1007\/s13555-020-00414-7.","journal-title":"Dermatol Ther"},{"issue":"12","key":"6141_CR28","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3390\/toxins10120535","volume":"10","author":"M Field","year":"2018","unstructured":"Field M, Splevins A, Picaut P, van der Schans M, Langenberg J, Noort D, et al. Abobotulinumtoxina (Dysport\u00ae), Onabotulinumtoxina (Botox\u00ae), and Incobotulinumtoxina (Xeomin\u00ae) neurotoxin content and potential implications for duration of response in patients. Toxins. 2018;10(12):535. https:\/\/doi.org\/10.3390\/toxins10120535.","journal-title":"Toxins"},{"issue":"3","key":"6141_CR29","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/jocd.12667","volume":"17","author":"P Sirithanabadeekul","year":"2018","unstructured":"Sirithanabadeekul P, Lapsomboonsiri S, Rungjang A, Thanasarnaksorn W. Split face comparison between common concentration vs double dilution of intradermal Abobotulinum toxin type A (Dysport) injection for facial lifting in Asians. J Cosmet Dermatol. 2018;17(3):355\u201360. https:\/\/doi.org\/10.1111\/jocd.12667.","journal-title":"J Cosmet Dermatol"},{"key":"6141_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.12289","author":"R Wanitphakdeedecha","year":"2016","unstructured":"Wanitphakdeedecha R, Ungaksornpairote C, Kaewkes A, Rojanavanich V, Phothong W, Manuskiatti W. The comparison between intradermal injection of AbobotulinumtoxinA and normal saline for face-lifting: a split-face randomized controlled trial. J Cosmet Dermatol. 2016. https:\/\/doi.org\/10.1111\/jocd.12289.","journal-title":"J Cosmet Dermatol"},{"issue":"12","key":"6141_CR31","first-page":"1363","volume":"12","author":"D Hexsel","year":"2013","unstructured":"Hexsel D, Brum C, Porto MD, Soirefmann M, Siega C, Schilling-Souza J, et al. Quality of life and satisfaction of patients after full-face injections of Abobotulinum toxin type A: a randomized, phase IV clinical trial. J Drugs Dermatol. 2013;12(12):1363\u20137.","journal-title":"J Drugs Dermatol"},{"key":"6141_CR32","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S41537","author":"T Rappl","year":"2013","unstructured":"Rappl T, Parvizi D, Friedl H, Wiedner M, May S, Kranzelbinder B, et al. Clinical, cosmetic and investigational dermatology onset and duration of effect of IncobotulinumtoxinA, OnabotulinumtoxinA, and AbobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clin Cosmet Investig Dermatol. 2013. https:\/\/doi.org\/10.2147\/CCID.S41537.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"6141_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/toxins13100694","author":"S Kongsaengdao","year":"2021","unstructured":"Kongsaengdao S, Arayawithchanont A, Samintharapanya K, Rojanapitayakorn P, Maneeton B, Maneeton N. Low-dose neubotulinum toxin a versus low-dose Abobotulinum toxin A injection for the treatment of cervical dystonia: a multicenter 48-week prospective double-blinded randomized crossover design study. Toxins. 2021. https:\/\/doi.org\/10.3390\/toxins13100694.","journal-title":"Toxins"},{"issue":"2","key":"6141_CR34","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1007\/s00415-022-11395-2","volume":"270","author":"H Hefter","year":"2023","unstructured":"Hefter H, Rosenthal D, Jansen A, Brauns R, \u00dcrer B, Bigalke H, et al. Significantly lower antigenicity of Incobotulinumtoxin than Abo- or Onabotulinumtoxin. J Neurol. 2023;270(2):788\u201396. https:\/\/doi.org\/10.1007\/s00415-022-11395-2.","journal-title":"J Neurol"},{"key":"6141_CR35","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.2147\/DDDT.S138489","volume":"11","author":"Y Feng","year":"2017","unstructured":"Feng Y, Liu W, Pan L, Jiang C, Zhang C, Lu Y, et al. Comparison of neurotoxic potency between a novel ChinbotulinumtoxinA with OnabotulinumtoxinA, IncobotulinumtoxinA and LanbotulinumtoxinA in rats. Drug Des Dev Ther. 2017;11:1927\u201339. https:\/\/doi.org\/10.2147\/DDDT.S138489.","journal-title":"Drug Des Dev Ther"},{"key":"6141_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjab015","author":"R Kandari","year":"2021","unstructured":"Kandari R, Imran A, Sethi N, Rahman E, Mosahebi A. Onabotulinumtoxin type-A dosage for upper face expression lines in males: a systematic review of current recommendations. Aesthet Surg J. 2021. https:\/\/doi.org\/10.1093\/asj\/sjab015.","journal-title":"Aesthet Surg J"},{"issue":"7","key":"6141_CR37","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1111\/head.13849","volume":"60","author":"R Burstein","year":"2020","unstructured":"Burstein R, Blumenfeld AM, Silberstein SD, Manack Adams A, Brin MF. Mechanism of action of OnabotulinumtoxinA in chronic migraine: a narrative review. Headache J Head Face Pain. 2020;60(7):1259\u201372.","journal-title":"Headache J Head Face Pain"},{"key":"6141_CR38","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2013.769041","author":"JH Lee","year":"2014","unstructured":"Lee JH, Lee JH, Park JH, Lee SK, Han KH, Kim SD, et al. Efficacy and safety of Incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with Onabotulinum toxin A. J Dermatol Treat. 2014. https:\/\/doi.org\/10.3109\/09546634.2013.769041.","journal-title":"J Dermatol Treat"},{"key":"6141_CR39","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000704","author":"A Carruthers","year":"2016","unstructured":"Carruthers A, Carruthers J, Fagien S, Lei X, Kolodziejczyk J, Brin MF. Repeated OnabotulinumtoxinA treatment of glabellar lines at rest over three treatment cycles. Dermatol Surg. 2016. https:\/\/doi.org\/10.1097\/DSS.0000000000000704.","journal-title":"Dermatol Surg"},{"key":"6141_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s00266-017-0844-9","author":"K Harii","year":"2017","unstructured":"Harii K, Kawashima M, Furuyama N, Lei X, Hopfinger R, Lee E. OnabotulinumtoxinA (Botox) in the treatment of crow\u2019s feet lines in japanese subjects. Aesthet Plast Surg. 2017. https:\/\/doi.org\/10.1007\/s00266-017-0844-9.","journal-title":"Aesthet Plast Surg"},{"key":"6141_CR41","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S397999","author":"DC Rupp","year":"2023","unstructured":"Rupp DC, Canty D, Rh\u00e9aume C, Sondergaard B, Ni\u00f1o C, Broide RS, et al. A preclinical study comparing the activity and potency of OnabotulinumtoxinA and PrabotulinumtoxinA. Clin Cosmet Investig Dermatol. 2023. https:\/\/doi.org\/10.2147\/CCID.S397999.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"6141_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23254","author":"M Naumann","year":"2010","unstructured":"Naumann M, Carruthers A, Carruthers J, Aurora SK, Zafonte R, Abu-Shakra S, et al. Meta-analysis of neutralizin1g antibody conversion with OnabotulinumtoxinA (BOTOX\u00ae) across multiple indications. Mov Disord. 2010. https:\/\/doi.org\/10.1002\/mds.23254.","journal-title":"Mov Disord"},{"key":"6141_CR43","doi-asserted-by":"publisher","DOI":"10.1097\/GOX.0000000000002079","author":"Y Wu","year":"2019","unstructured":"Wu Y, Wang G, Li C, Mao C, Lei X, Lee E. Safety and Efficacy of Onabotulinumtoxina for treatment of crow\u2019s feet lines in chinese subjects. Plast Reconstr Surg Glob Open. 2019. https:\/\/doi.org\/10.1097\/GOX.0000000000002079.","journal-title":"Plast Reconstr Surg Glob Open"},{"issue":"1","key":"6141_CR44","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/j.1468-3083.2012.04681.x","volume":"27","author":"DH Lee","year":"2013","unstructured":"Lee DH, Kang SM, Feneran A, Youn CS, Kim JK, Cho S, et al. RimabotulinumtoxinB vs. OnabotulinumtoxinA for the treatment of forehead lines: an evaluator-blind, randomized, pilot study. J Eur Acad Dermatol Venereol. 2013;27(1):e1\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"6141_CR45","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/asj\/sjy116","volume":"39","author":"JL Cohen","year":"2019","unstructured":"Cohen JL, Swift A, Solish N, Fagien S, Glaser DA. OnabotulinumtoxinA and hyaluronic acid in facial wrinkles and folds: a prospective, open-label comparison. Aesthet Surg J. 2019;39(2):187\u2013200.","journal-title":"Aesthet Surg J"},{"key":"6141_CR46","doi-asserted-by":"publisher","first-page":"S274","DOI":"10.1097\/DSS.0000000000001414","volume":"43","author":"S Fagien","year":"2017","unstructured":"Fagien S, Cohen JL, Coleman W, Monheit G, Carruthers J, Street J, et al. Forehead line treatment with OnabotulinumtoxinA in subjects with forehead and glabellar facial rhytids: a phase 3 study. Dermatol Surg. 2017;43:S274\u201384.","journal-title":"Dermatol Surg"},{"issue":"5","key":"6141_CR47","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1097\/DSS.0000000000000757","volume":"42","author":"L Baumann","year":"2016","unstructured":"Baumann L, Dayan S, Connolly S, Silverberg N, Lei X, Drinkwater A, et al. Duration of clinical efficacy of OnabotulinumtoxinA in crow\u2019s feet lines: results from two multicenter, randomized, controlled trials. Dermatol Surg. 2016;42(5):598.","journal-title":"Dermatol Surg"},{"key":"6141_CR48","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000128","author":"A Carruthers","year":"2014","unstructured":"Carruthers A, Bruce S, De Coninck A, Connolly S, Cox SE, Davis PG, et al. Efficacy and safety of Onabotulinumtoxina for the treatment of crows feet lines: a multicenter randomized controlled trial. Dermatol Surg. 2014. https:\/\/doi.org\/10.1097\/DSS.0000000000000128.","journal-title":"Dermatol Surg"},{"issue":"5","key":"6141_CR49","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1097\/PRS.0000000000001255","volume":"135","author":"RH Yeilding","year":"2015","unstructured":"Yeilding RH, Fezza JP. A Prospective, split-face, randomized, double-blind study comparing OnabotulinumtoxinA to IncobotulinumtoxinA for upper face wrinkles. Plast Reconstr Surg. 2015;135(5):1328\u201335.","journal-title":"Plast Reconstr Surg"},{"key":"6141_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/toxins15050342","author":"J Jankovic","year":"2023","unstructured":"Jankovic J, Carruthers J, Naumann M, Ogilvie P, Boodhoo T, Attar M, et al. Neutralizing antibody formation with OnabotulinumtoxinA (BOTOX\u00ae) treatment from global registration studies across multiple indications: a meta-analysis. Toxins. 2023. https:\/\/doi.org\/10.3390\/toxins15050342.","journal-title":"Toxins"},{"issue":"8","key":"6141_CR51","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1097\/DSS.0000000000000424","volume":"41","author":"JK Rivers","year":"2015","unstructured":"Rivers JK, Bertucci V, McGillivray W, Muhn C, Rosen N, Solish N, et al. Subject satisfaction with OnabotulinumtoxinA treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure. Dermatol Surg. 2015;41(8):950\u20139.","journal-title":"Dermatol Surg"},{"key":"6141_CR52","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjac253","author":"E Rahman","year":"2023","unstructured":"Rahman E, Mosahebi A, Carruthers JDA, Carruthers A. The Efficacy and duration of Onabotulinum toxin A in improving upper facial expression lines with 64-unit dose optimization: a systematic review and meta-analysis with trial sequential analysis of the randomized controlled trials. Aesthet Surg J. 2023. https:\/\/doi.org\/10.1093\/asj\/sjac253.","journal-title":"Aesthet Surg J"},{"key":"6141_CR53","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17217","author":"KH Yoo","year":"2021","unstructured":"Yoo KH, Park SJ, Han HS, Won CH, Lee YW, Kim BJ. Randomized double-blind active-controlled multicentre phase III clinical trial with two stages to assess the safety and efficacy of Letibotulinum Toxin a vs Onabotulinum toxin a for subjects with moderate to severe crow\u2019s feet s. J Eur Acad Dermatol Venereol. 2021. https:\/\/doi.org\/10.1111\/jdv.17217.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"6141_CR54","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1097\/DSS.0000000000001612","volume":"44","author":"K De Boulle","year":"2018","unstructured":"De Boulle K, Werschler WP, Gold MH, Bruce S, Sattler G, Ogilvie P, et al. Phase 3 study of OnabotulinumtoxinA distributed between frontalis, glabellar complex, and lateral canthal areas for treatment of upper facial lines. Dermatol Surg. 2018;44(11):1437\u201348.","journal-title":"Dermatol Surg"},{"issue":"6","key":"6141_CR55","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1097\/DSS.0000000000000340","volume":"41","author":"A Carruthers","year":"2015","unstructured":"Carruthers A, Sadick N, Brandt F, de Almeida ART, Fagien S, Goodman GJ, et al. Evolution of facial aesthetic treatment over five or more years: a retrospective cross-sectional analysis of continuous OnabotulinumtoxinA treatment. Dermatol Surg. 2015;41(6):693\u2013701.","journal-title":"Dermatol Surg"},{"key":"6141_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2020.11.411","author":"J Jankovic","year":"2021","unstructured":"Jankovic J, Carruthers J, Naumann M, Boodhoo T, Gupta S, Attar M, et al. Neutralizing antibody conversion with OnabotulinumtoxinA from global studies across multiple indications in nearly 30,000 patient records: a meta-analysis. Toxicon. 2021. https:\/\/doi.org\/10.1016\/j.toxicon.2020.11.411.","journal-title":"Toxicon"},{"key":"6141_CR57","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000002216","author":"MD Palm","year":"2020","unstructured":"Palm MD, Few J, Patel T, Safa M, Drinkwater A, Mao C, et al. Efficacy, patient-reported outcomes, and safety for millennial subjects treated with OnabotulinumtoxinA for moderate to severe horizontal forehead lines. Dermatol Surg Off Publ Am Soc Dermatol Surg. 2020. https:\/\/doi.org\/10.1097\/DSS.0000000000002216.","journal-title":"Dermatol Surg Off Publ Am Soc Dermatol Surg"},{"issue":"1","key":"6141_CR58","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/DSS.0000000000000220","volume":"41","author":"M Moers-Carpi","year":"2015","unstructured":"Moers-Carpi M, et al. Efficacy and safety of Onabotulinumtoxina for treating crow\u2019s feet lines alone or in combination with glabellar lines: a multicenter randomized controlled trial. Dermatol Surg. 2015;41(1):102\u201312.","journal-title":"Dermatol Surg"},{"key":"6141_CR59","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000002047","author":"TC Keaney","year":"2020","unstructured":"Keaney TC, Cavallini M, Leys C, Rossi A, Drinkwater A, Brown SM, et al. Efficacy patient-reported outcomes, and safety in male subjects treated with OnabotulinumtoxinA for improvement of moderate to severe horizontal forehead lines. Dermatol Surg. 2020. https:\/\/doi.org\/10.1097\/DSS.0000000000002047.","journal-title":"Dermatol Surg"},{"key":"6141_CR60","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000220","author":"M Moers-Carpi","year":"2015","unstructured":"Moers-Carpi M, Carruthers J, Fagien S, Lupo M, Delmar H, Jones D, et al. Efficacy and safety of Onabotulinumtoxina for treating crow\u2019s feet lines alone or in combination with glabellar lines: a multicentre, randomized, controlled trial. Dermatol Surg. 2015. https:\/\/doi.org\/10.1097\/DSS.0000000000000220.","journal-title":"Dermatol Surg"},{"key":"6141_CR61","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000001779","author":"P Ogilvie","year":"2019","unstructured":"Ogilvie P, Rivkin AZ, Dayan S, Yoelin SG, Weichman BM, Garcia JK. OnabotulinumtoxinA for treatment of forehead and glabellar lines: subject-reported satisfaction and impact from a phase 3 double-blind study. Dermatol Surg. 2019. https:\/\/doi.org\/10.1097\/DSS.0000000000001779.","journal-title":"Dermatol Surg"},{"key":"6141_CR62","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000001206","author":"J Carruthers","year":"2017","unstructured":"Carruthers J, Solish N, Humphrey S, Rosen N, Muhn C, Bertucci V, et al. Injectable Daxibotulinumtoxina for the treatment of glabellar lines: a phase 2 randomized dose-ranging double-blind multicenter comparison with Onabotulinumtoxina and placebo. Dermatol Surg. 2017. https:\/\/doi.org\/10.1097\/DSS.0000000000001206.","journal-title":"Dermatol Surg"},{"key":"6141_CR63","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjac210","author":"N Solish","year":"2022","unstructured":"Solish N, Ascher B, Avelar RL, Bertucci V, Bodokh I, Carruthers J, et al. PrabotulinumtoxinA vs OnabotulinumtoxinA for the treatment of adult males with moderate to severe glabellar lines: post-hoc analyses of the phase III clinical study data. Aesthet Surg J. 2022. https:\/\/doi.org\/10.1093\/asj\/sjac210.","journal-title":"Aesthet Surg J"},{"key":"6141_CR64","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000357","author":"J Carruthers","year":"2015","unstructured":"Carruthers J, Rivkin A, Donofrio L, Bertucci V, Somogyi C, Lei X, et al. A multicenter randomized double-blind placebo-controlled study to evaluate the efficacy and safety of repeated OnabotulinumtoxinA treatments in subjects with crow\u2019s feet lines and glabellar lines. Dermatol Surg. 2015. https:\/\/doi.org\/10.1097\/DSS.0000000000000357.","journal-title":"Dermatol Surg"},{"issue":"5","key":"6141_CR65","first-page":"47","volume":"16","author":"G Vasile","year":"2023","unstructured":"Vasile G, Green C, Bhatti H, Ilyas M, Buckley C, Saleeby E, et al. OnabotulinumtoxinA versus PrabotulinumtoxinA-Xvfs: a randomized triple-blind, split-face study on the time to onset rhytid appearance and patient satisfaction in forehead and glabellar lines. J Clin Aesthet Dermatol. 2023;16(5):47.","journal-title":"J Clin Aesthet Dermatol"},{"key":"6141_CR66","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjz110","author":"BJ Rzany","year":"2020","unstructured":"Rzany BJ, Ascher B, Avelar RL, Bergdahl J, Bertucci V, Bodokh I, et al. A multicenter randomized double-blind placebo-controlled single-dose phase III non-inferiority study comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult patients. Aesthet Surg J. 2020. https:\/\/doi.org\/10.1093\/asj\/sjz110.","journal-title":"Aesthet Surg J"},{"key":"6141_CR67","doi-asserted-by":"publisher","DOI":"10.17116\/plast.hirurgia202002167","author":"EV Ikonnikova","year":"2020","unstructured":"Ikonnikova EV, Kruglova LS, Savushkina IY. A rare complication of Botulinum toxin injection. Plast Surg Aesthet Med. 2020. https:\/\/doi.org\/10.17116\/plast.hirurgia202002167.","journal-title":"Plast Surg Aesthet Med"},{"key":"6141_CR68","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.15016","author":"D Lai","year":"2022","unstructured":"Lai D, Liu H, Kong L, Cheng S. Delayed complication of Botulinum toxin and hyaluronic acid filler injections: a case report. J Cosmet Dermatol. 2022. https:\/\/doi.org\/10.1111\/jocd.15016.","journal-title":"J Cosmet Dermatol"},{"key":"6141_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8635(03)00122-0","author":"AW Klein","year":"2003","unstructured":"Klein AW. Complications with the use of Botulinum toxin. Dermatol Clin. 2003. https:\/\/doi.org\/10.1016\/S0733-8635(03)00122-0.","journal-title":"Dermatol Clin"},{"key":"6141_CR70","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.14160","author":"G Kroumpouzos","year":"2021","unstructured":"Kroumpouzos G, Kassir M, Gupta M, Patil A, Goldust M. Complications of Botulinum toxin A: an update review. J Cosmet Dermatol. 2021. https:\/\/doi.org\/10.1111\/jocd.14160.","journal-title":"J Cosmet Dermatol"},{"key":"6141_CR71","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.13266","author":"M Kassir","year":"2020","unstructured":"Kassir M, Gupta M, Galadari H, Kroumpouzos G, Katsambas A, Lotti T, et al. Complications of Botulinum toxin and fillers: a narrative review. J Cosmet Dermatol. 2020. https:\/\/doi.org\/10.1111\/jocd.13266.","journal-title":"J Cosmet Dermatol"},{"key":"6141_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.fsc.2004.04.008","author":"AJ Vartanian","year":"2003","unstructured":"Vartanian AJ, Dayan SH. Complications of Botulinum toxin A use in facial rejuvenation. Facial Plast Surg Clin N Am. 2003. https:\/\/doi.org\/10.1016\/j.fsc.2004.04.008.","journal-title":"Facial Plast Surg Clin N Am"},{"key":"6141_CR73","doi-asserted-by":"publisher","DOI":"10.3109\/09273970903303860","author":"F Rowe","year":"2009","unstructured":"Rowe F, Noonan C. Complications of Botulinum toxin A and their adverse effects. Strabismus. 2009. https:\/\/doi.org\/10.3109\/09273970903303860.","journal-title":"Strabismus"},{"key":"6141_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2003.12.026","author":"AW Klein","year":"2004","unstructured":"Klein AW. Contraindications and complications with the use of Botulinum toxin. Clin Dermatol. 2004. https:\/\/doi.org\/10.1016\/j.clindermatol.2003.12.026.","journal-title":"Clin Dermatol"},{"key":"6141_CR75","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.13667","author":"M Landau","year":"2020","unstructured":"Landau M, Nestor MS, de Almeida AT, Al-Niaimi F. Botulinum toxin complications in registered and off-label aesthetic indications. J Cosmet Dermatol. 2020. https:\/\/doi.org\/10.1111\/jocd.13667.","journal-title":"J Cosmet Dermatol"},{"key":"6141_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2020.02.016","author":"KC Lee","year":"2020","unstructured":"Lee KC, Pascal AB, Halepas S, Koch A. What are the most commonly reported complications with cosmetic Botulinum toxin type A treatments? J Oral Maxillofac Surg. 2020. https:\/\/doi.org\/10.1016\/j.joms.2020.02.016.","journal-title":"J Oral Maxillofac Surg"},{"key":"6141_CR77","doi-asserted-by":"publisher","DOI":"10.1007\/s00266-020-01983-w","author":"N Sethi","year":"2021","unstructured":"Sethi N, Singh S, DeBoulle K, Rahman E. A review of complications due to the use of Botulinum toxin A for cosmetic indications. Aesthet Plast Surg. 2021. https:\/\/doi.org\/10.1007\/s00266-020-01983-w.","journal-title":"Aesthet Plast Surg"},{"key":"6141_CR78","doi-asserted-by":"publisher","DOI":"10.1007\/s00266-004-0031-7","author":"MC Ferreira","year":"2004","unstructured":"Ferreira MC, Salles AG, Gimenez R, Soares MFD. Complications with the use of Botulinum toxin type A in facial rejuvenation: report of 8 cases. Aesthet Plast Surg. 2004. https:\/\/doi.org\/10.1007\/s00266-004-0031-7.","journal-title":"Aesthet Plast Surg"},{"key":"6141_CR79","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjac036","author":"D Zargaran","year":"2022","unstructured":"Zargaran D, Zoller F, Zargaran A, Rahman E, Woollard A, Weyrich T, et al. Complications of cosmetic Botulinum toxin A injections to the upper face: a systematic review and meta-analysis. Aesthet Surg J. 2022. https:\/\/doi.org\/10.1093\/asj\/sjac036.","journal-title":"Aesthet Surg J"},{"key":"6141_CR80","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.12473","author":"HLP Peng","year":"2018","unstructured":"Peng HLP, Peng JH. Complications of Botulinum toxin injection for masseter hypertrophy: incidence rate from 2036 treatments and summary of causes and preventions. J Cosmet Dermatol. 2018. https:\/\/doi.org\/10.1111\/jocd.12473.","journal-title":"J Cosmet Dermatol"},{"key":"6141_CR81","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjac002","author":"V Bertucci","year":"2023","unstructured":"Bertucci V, Green JB, Fezza JP, Brown J, Gallagher CJ, Solish N. Impact of glabellar injection technique With DaxibotulinumtoxinA for injection on brow position. Aesthet Surg J. 2023. https:\/\/doi.org\/10.1093\/asj\/sjac002.","journal-title":"Aesthet Surg J"},{"key":"6141_CR82","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01631-w","author":"N Solish","year":"2021","unstructured":"Solish N, Carruthers J, Kaufman J, Rubio RG, Gross TM, Gallagher CJ. Overview of DaxibotulinumtoxinA for injection: a novel formulation of Botulinum toxin type A. Drugs. 2021. https:\/\/doi.org\/10.1007\/s40265-021-01631-w.","journal-title":"Drugs"},{"key":"6141_CR83","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12613","author":"J Jankovic","year":"2018","unstructured":"Jankovic J, Truong D, Patel AT, Brashear A, Evatt M, Rubio RG, et al. Injectable DaxibotulinumtoxinA in cervical dystonia: a phase 2 dose-escalation multicenter study. Mov Disord Clin Pract. 2018. https:\/\/doi.org\/10.1002\/mdc3.12613.","journal-title":"Mov Disord Clin Pract"},{"key":"6141_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2018.11.103","author":"S Guillen-Fabi","year":"2018","unstructured":"Guillen-Fabi S, Green JB, Liu Y, Rubio RG, Gallagher CJ. SAKURA-3, a large open-label safety study of DaxibotulinumtoxinA for injection in glabellar lines. Toxicon. 2018. https:\/\/doi.org\/10.1016\/j.toxicon.2018.11.103.","journal-title":"Toxicon"},{"key":"6141_CR85","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000003637","author":"JS Dover","year":"2023","unstructured":"Dover JS, Humphrey SD, Lorenc ZP, Shamban A, Gross TM, Rubio RG, et al. Treatment of upper facial lines with DaxibotulinumtoxinA for injection: results from an open-label phase 2 study. Dermatol Surg. 2023. https:\/\/doi.org\/10.1097\/DSS.0000000000003637.","journal-title":"Dermatol Surg"},{"key":"6141_CR86","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjac246","author":"N Solish","year":"2023","unstructured":"Solish N, Burgess CM, Weinkle SH, Ablon G, Brown J, Kooken K, et al. Efficacy and safety of DaxibotulinumtoxinA for injection in the treatment of glabellar lines by age and race: subgroup analysis of the SAKURA clinical trials. Aesthet Surg J. 2023. https:\/\/doi.org\/10.1093\/asj\/sjac246.","journal-title":"Aesthet Surg J"},{"key":"6141_CR87","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000002463","author":"JB Green","year":"2021","unstructured":"Green JB, Mariwalla K, Coleman K, Ablon G, Weinkle SH, Gallagher CJ, et al. A large, open-label, phase 3 safety study of DaxibotulinumtoxinA for injection in glabellar lines: a focus on safety from the SAKURA 3 study. Dermatol Surg Off Publ Am Soc Dermatol. 2021. https:\/\/doi.org\/10.1097\/DSS.0000000000002463.","journal-title":"Dermatol Surg Off Publ Am Soc Dermatol"},{"key":"6141_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.1313","author":"V Bertucci","year":"2020","unstructured":"Bertucci V, Solish N, Kaufman-Janette J, Yoelin S, Shamban A, Schlessinger J, et al. DaxibotulinumtoxinA for injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). J Am Acad Dermatol. 2020. https:\/\/doi.org\/10.1016\/j.jaad.2019.06.1313.","journal-title":"J Am Acad Dermatol"},{"key":"6141_CR89","doi-asserted-by":"publisher","DOI":"10.1177\/1060028020943527","author":"MB Gadarowski","year":"2021","unstructured":"Gadarowski MB, Ghamrawi RI, Taylor SL, Feldman SR. PrabotulinumtoxinA-Xvfs for the treatment of moderate-to-severe glabellar lines. Ann Pharmacother. 2021. https:\/\/doi.org\/10.1177\/1060028020943527.","journal-title":"Ann Pharmacother"},{"key":"6141_CR90","doi-asserted-by":"publisher","DOI":"10.3889\/oamjms.2022.9834","author":"S Murlistyarini","year":"2022","unstructured":"Murlistyarini S, Dani AA, Norawati L, Maria R, Arimuko A, Kusumawardani A, et al. Multicenter study: effectiveness and efficiency of prabotulinum toxin-A injection on wrinkles in forehead, crow\u2019s feet, and glabellar. Open Access Maced J Med Sci. 2022. https:\/\/doi.org\/10.3889\/oamjms.2022.9834.","journal-title":"Open Access Maced J Med Sci"},{"key":"6141_CR91","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000001903","author":"KR Beer","year":"2019","unstructured":"Beer KR, Shamban AT, Avelar RL, Gross JE, Jonker A. Efficacy and safety of PrabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatol Surg. 2019. https:\/\/doi.org\/10.1097\/DSS.0000000000001903.","journal-title":"Dermatol Surg"},{"key":"6141_CR92","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000003456","author":"P Ogilvie","year":"2022","unstructured":"Ogilvie P, Jones DH, Avelar RL, Jonker A, Monroe R, Carruthers J. PrabotulinumtoxinA for treatment of millennials with moderate to severe glabellar lines: post hoc analyses of the phase III clinical study data. Dermatol Surg. 2022. https:\/\/doi.org\/10.1097\/DSS.0000000000003456.","journal-title":"Dermatol Surg"},{"key":"6141_CR93","doi-asserted-by":"publisher","DOI":"10.1093\/asjof\/ojae013","author":"K Taylor-Barnes","year":"2024","unstructured":"Taylor-Barnes K. Real-world patient experience with PrabotulinumtoxinA in the United Kingdom: a single-center survey and analysis of 254 patients. Aesthet Surg J Open Forum. 2024. https:\/\/doi.org\/10.1093\/asjof\/ojae013.","journal-title":"Aesthet Surg J Open Forum"},{"key":"6141_CR94","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12196326","author":"SK Lee","year":"2023","unstructured":"Lee SK, Kim MS, Kwon SH, Chung BY, Han SH, Kim HJ. Efficacy, safety, and subject satisfaction of PrabotulinumtoxinA for moderate-to-severe crow\u2019s feet: a phase IV, multicentre, double-blind, randomized, placebo-controlled trial. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12196326.","journal-title":"J Clin Med"},{"key":"6141_CR95","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000002864","author":"SC Taylor","year":"2021","unstructured":"Taylor SC, Grimes PE, Joseph JH, Jonker A, Avelar RL. PrabotulinumtoxinA for the treatment of moderate-to-severe glabellar lines in adult patients with skin of color: post hoc analyses of the US phase III clinical study data. Dermatol Surg. 2021. https:\/\/doi.org\/10.1097\/DSS.0000000000002864.","journal-title":"Dermatol Surg"},{"key":"6141_CR96","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.15783","author":"SE Cox","year":"2023","unstructured":"Cox SE, Ascher B, Avelar RL, Beer KR, Carruthers J, Cartier H, et al. PrabotulinumtoxinA for the treatment of glabellar lines in adults, 65 years of age and older: the fourth in a series of post hoc analyses of the phase III clinical study data. J Cosmet Dermatol. 2023. https:\/\/doi.org\/10.1111\/jocd.15783.","journal-title":"J Cosmet Dermatol"},{"issue":"12","key":"6141_CR97","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1093\/asj\/sjaa382","volume":"41","author":"ZP Lorenc","year":"2021","unstructured":"Lorenc ZP, Adelglass JM, Avelar RL, Baumann L, Beer KR, Cohen JL, et al. The second of two one-year, multicenter, open-label, repeat-dose, phase II safety studies of PrabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult patients. Aesthet Surg J. 2021;41(12):1423\u201338. https:\/\/doi.org\/10.1093\/asj\/sjaa382.","journal-title":"Aesthet Surg J"},{"issue":"12","key":"6141_CR98","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1093\/asj\/sjaa383","volume":"41","author":"J Kaufman-Janette","year":"2021","unstructured":"Kaufman-Janette J, Avelar RL, Biesman BS, Draelos ZD, Gross JE, Jones DH, et al. The first of two one-year, multicenter, open-label, repeat-dose, phase II safety studies of PrabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult patients. Aesthet Surg J. 2021;41(12):1409\u201322. https:\/\/doi.org\/10.1093\/asj\/sjaa383.","journal-title":"Aesthet Surg J"},{"key":"6141_CR99","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjab058","author":"E Rahman","year":"2021","unstructured":"Rahman E, Alhitmi HK, Mosahebi A. Immunogenicity to Botulinum toxin type A: a systematic review with meta-analysis across therapeutic indications. Aesthet Surg J. 2021. https:\/\/doi.org\/10.1093\/asj\/sjab058.","journal-title":"Aesthet Surg J"},{"key":"6141_CR100","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0000000000008904","author":"E Rahman","year":"2022","unstructured":"Rahman E, Banerjee PS, Asghar A, Gupta NK, Mosahebi A. Botulinum toxin type A immunogenicity across multiple indications: an overview systematic review. Plast Reconstr Surg. 2022. https:\/\/doi.org\/10.1097\/PRS.0000000000008904.","journal-title":"Plast Reconstr Surg"},{"key":"6141_CR101","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0000000000011748","author":"E Rahman","year":"2024","unstructured":"Rahman E, Carruthers JDA, Rao P, Yu N, Philipp-Dormston WG, Webb WR. Predictive modelling of immunogenicity to Botulinumtoxin A treatments for glabellar lines. Plast Reconstr Surg. 2024. https:\/\/doi.org\/10.1097\/PRS.0000000000011748.","journal-title":"Plast Reconstr Surg"},{"key":"6141_CR102","doi-asserted-by":"publisher","DOI":"10.5114\/ps\/140080","author":"R Grillo","year":"2021","unstructured":"Grillo R. Bibliometric trending analysis of complications related to facial non-surgical aesthetic procedures: a retrospective study. Protet Stomatol. 2021. https:\/\/doi.org\/10.5114\/ps\/140080.","journal-title":"Protet Stomatol"},{"key":"6141_CR103","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.5616","author":"JY Park","year":"2021","unstructured":"Park JY, Cho SI, Hur K, Lee DH. Intradermal microdroplet injection of diluted Incobotulinumtoxin-A for sebum control face lifting and pore size improvement. J Drugs Dermatol JDD. 2021. https:\/\/doi.org\/10.36849\/JDD.5616.","journal-title":"J Drugs Dermatol JDD"},{"key":"6141_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2020.11.460","author":"J-Y Park","year":"2021","unstructured":"Park J-Y, Cho SI, Hur K, Lee DH. IncobotulinumtoxinA injection for sebum control, face lifting, and pore size improvement. Toxicon. 2021. https:\/\/doi.org\/10.1016\/j.toxicon.2020.11.460.","journal-title":"Toxicon"},{"key":"6141_CR105","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-013-0998-9","author":"DD Truong","year":"2013","unstructured":"Truong DD, Gollomp SM, Jankovic J, Lewitt PA, Marx M, Hanschmann A, et al. Sustained efficacy and safety of repeated IncobotulinumtoxinA (Xeomin \u00ae) injections in Blepharospasm. J Neural Transm. 2013. https:\/\/doi.org\/10.1007\/s00702-013-0998-9.","journal-title":"J Neural Transm"},{"key":"6141_CR106","doi-asserted-by":"publisher","DOI":"10.1111\/dsu.12100","author":"A Carruthers","year":"2013","unstructured":"Carruthers A, Carruthers J, Coleman WP, Donofrio L, Flynn T, Gold M, et al. Multicenter, randomized, phase III study of a single dose of IncobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Dermatol Surg. 2013. https:\/\/doi.org\/10.1111\/dsu.12100.","journal-title":"Dermatol Surg"},{"issue":"8","key":"6141_CR107","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/mds.23658","volume":"26","author":"J Jankovic","year":"2011","unstructured":"Jankovic J, Comella C, Hanschmann A, Grafe S. Efficacy and safety of IncobotulinumtoxinA (NT 201, Xeomin) in the treatment of Blepharospasm-A randomized trial. Mov Disord. 2011;26(8):1521\u20138. https:\/\/doi.org\/10.1002\/mds.23658.","journal-title":"Mov Disord"},{"key":"6141_CR108","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.6377","author":"M Kerscher","year":"2021","unstructured":"Kerscher M, Fabi S, Fischer T, Gold M, Joseph J, Prager W, et al. IncobotulinumtoxinA demonstrates safety and prolonged duration of effect in a dose-ranging study for glabellar lines. J Drugs Dermatology JDD. 2021. https:\/\/doi.org\/10.36849\/JDD.6377.","journal-title":"J Drugs Dermatology JDD"},{"key":"6141_CR109","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S391709","author":"ALG da Cunha","year":"2023","unstructured":"da Cunha ALG, Vasconcelos R, Di Sessa D, Sampaio G, Ramalhoto P, Zampieri BF, et al. IncobotulinumtoxinA for the treatment of glabella and forehead dynamic lines: a real-life longitudinal case series. Clin Cosmet Investig Dermatol. 2023. https:\/\/doi.org\/10.2147\/CCID.S391709.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"2","key":"6141_CR110","first-page":"24","volume":"17","author":"SC Barbarino","year":"2024","unstructured":"Barbarino SC, Day D, Rivkin A, Levine J, Fezza J. Evaluating the use of IncobotulinumtoxinA in combination with calcium hydroxylapatite with integral lidocaine for improving chin profile projection aesthetics. J Clini Aesthet Dermatol. 2024;17(2):24\u20138.","journal-title":"J Clini Aesthet Dermatol"},{"key":"6141_CR111","doi-asserted-by":"publisher","DOI":"10.2340\/16501977-0796","author":"P Ka\u0148ovsk\u00fd","year":"2011","unstructured":"Ka\u0148ovsk\u00fd P, Slawek J, Denes Z, Platz T, Comes G, Grafe S, et al. Efficacy and safety of treatment with Incobotulinum toxin A (Botulinum neurotoxin type a free from complexing proteins; Nt 201) in post-stroke upper limb spasticity. J Rehabil Med. 2011. https:\/\/doi.org\/10.2340\/16501977-0796.","journal-title":"J Rehabil Med"},{"key":"6141_CR112","doi-asserted-by":"publisher","DOI":"10.1111\/dsu.12160","author":"C William Hanke","year":"2013","unstructured":"William Hanke C, Narins RS, Brandt F, Cohen JL, Donofrio LM, Downie J, et al. A randomized placebo-controlled double-blind phase III trial investigating the efficacy and safety of Incobotulinumtoxin A in the treatment of glabellar frown lines using a stringent composite endpoint. Dermatol Surg. 2013. https:\/\/doi.org\/10.1111\/dsu.12160.","journal-title":"Dermatol Surg"},{"key":"6141_CR113","first-page":"33","volume":"33","author":"T Fischer","year":"2020","unstructured":"Fischer T, Sattler G, Prager W, Rzany B, Pavicic T, Gauglitz G, et al. Safety tolerability and efficacy of repeat-dose injections of IncobotulinumtoxinA in the treatment of upper facial lines results from a prospective open-label phase III study. J Drugs Dermatol JDD. 2020;33:33.","journal-title":"J Drugs Dermatol JDD"},{"key":"6141_CR114","unstructured":"Costa J, Esp\u00edrito-Santo Cl\u00e1udia C, Borges Ana A, Ferreira J, Coelho Miguel M, Moore P, Sampaio C. Botulinumtoxin type A therapy for Blepharospasm (Review). Cochrane Database of Systematic Reviews. 2009."},{"key":"6141_CR115","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1356093","author":"AE Hawlik","year":"2014","unstructured":"Hawlik AE, Freudenmann RW, Pinkhardt EH, Sch\u00f6nfeldt-Lecuona CJ, Gahr M. Botulinumtoxin Bei Der Behandlung Depressiver St\u00f6rungen: Eine Systematische \u00dcbersicht\u201d. Fortschritte der Neurologie Psychiatrie. 2014. https:\/\/doi.org\/10.1055\/s-0033-1356093.","journal-title":"Fortschritte der Neurologie Psychiatrie"},{"key":"6141_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.06.054","author":"C Dunn","year":"2022","unstructured":"Dunn C, Nyckowski T, Ambur A. 33263 rare cutaneous adverse effects of Botulinumtoxin A: a review. J Am Acad Dermatol. 2022. https:\/\/doi.org\/10.1016\/j.jaad.2022.06.054.","journal-title":"J Am Acad Dermatol"},{"key":"6141_CR117","doi-asserted-by":"publisher","DOI":"10.1097\/GOX.0000000000004217","author":"JY Park","year":"2022","unstructured":"Park JY, Corduff N, Frevert J, Wanitphakdeedecha R, Chao YYY. Immunogenicity associated with aesthetic Botulinumtoxin A: a survey of Asia-Pacific physicians\u2019 experiences and recommendations. Plast Reconstr Surg Glob Open. 2022. https:\/\/doi.org\/10.1097\/GOX.0000000000004217.","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"6141_CR118","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33119-1","author":"MB Lewis","year":"2018","unstructured":"Lewis MB. The interactions between Botulinum-toxin-based facial treatments and embodied emotions. Sci Rep. 2018. https:\/\/doi.org\/10.1038\/s41598-018-33119-1.","journal-title":"Sci Rep"},{"key":"6141_CR119","doi-asserted-by":"publisher","DOI":"10.1002\/mus.880171207","author":"JA Hamjian","year":"1994","unstructured":"Hamjian JA, Walker FO. Serial neurophysiological studies of intramuscular Botulinum-A toxin in humans. Muscle Nerve. 1994. https:\/\/doi.org\/10.1002\/mus.880171207.","journal-title":"Muscle Nerve"},{"key":"6141_CR120","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20003","author":"FJ Erbguth","year":"2004","unstructured":"Erbguth FJ. Historical notes on Botulism, Clostridium botulinum, Botulinum toxin, and the idea of the therapeutic use of the toxin. Mov Disord. 2004. https:\/\/doi.org\/10.1002\/mds.20003.","journal-title":"Mov Disord"},{"key":"6141_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/s0037-6337(05)70479-4","author":"TF Kirn","year":"2005","unstructured":"Kirn TF. Recent studies refute botox reconstitution myths. Skin Allergy News. 2005. https:\/\/doi.org\/10.1016\/s0037-6337(05)70479-4.","journal-title":"Skin Allergy News"},{"key":"6141_CR122","doi-asserted-by":"publisher","DOI":"10.25259\/csdm_15_2023","author":"RH Abbas","year":"2023","unstructured":"Abbas RH, Koshy RR, Fathima Y, Weerasekara RADK, Sherin Z, Selvakumar N, et al. The clinical approach to Botulinum toxin in dermatology: a literature review. Cosmoderma. 2023. https:\/\/doi.org\/10.25259\/csdm_15_2023.","journal-title":"Cosmoderma"},{"key":"6141_CR123","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0000000000001773","author":"MS Gart","year":"2015","unstructured":"Gart MS, Gutowski KA. Aesthetic uses of neuromodulators: current uses and future directions. Plast Reconstr Surg. 2015. https:\/\/doi.org\/10.1097\/PRS.0000000000001773.","journal-title":"Plast Reconstr Surg"},{"issue":"1","key":"6141_CR124","first-page":"95","volume":"2","author":"M Jain","year":"2014","unstructured":"Jain M, Bansal A, Agarwal D, Joshi M. Botox in dentistry: the healing side of a poison. J Adv Med Dent Sci. 2014;2(1):95\u20139.","journal-title":"J Adv Med Dent Sci"},{"key":"6141_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/S1064-7406(03)00022-1","author":"SH Dayan","year":"2003","unstructured":"Dayan SH, Bassichis BA. Evaluation of the patient for cosmetic Botox injections. Facial Plast Surg Clin N Am. 2003. https:\/\/doi.org\/10.1016\/S1064-7406(03)00022-1.","journal-title":"Facial Plast Surg Clin N Am"},{"key":"6141_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/S1064-7406(03)00070-1","author":"AJ Vartanian","year":"2003","unstructured":"Vartanian AJ, Dayan SH. Complications of Botulinum toxin A use in facial rejuvenation. Facial Plast Surg Clin N Am. 2003. https:\/\/doi.org\/10.1016\/S1064-7406(03)00070-1.","journal-title":"Facial Plast Surg Clin N Am"},{"key":"6141_CR127","doi-asserted-by":"publisher","DOI":"10.1007\/s12144-021-01452-w","author":"AO La Rosa","year":"2023","unstructured":"La Rosa AO, Villacampa J, Corradi G, Ingram GPD. The creepy, the bad and the ugly: exploring perceptions of moral character and social desirability in uncanny faces. Curr Psychol. 2023. https:\/\/doi.org\/10.1007\/s12144-021-01452-w.","journal-title":"Curr Psychol"},{"key":"6141_CR128","doi-asserted-by":"publisher","DOI":"10.7181\/acfs.2021.00003","author":"MY Park","year":"2021","unstructured":"Park MY, Ahn KY. Scientific review of the aesthetic uses of Botulinum toxin type A. Arch Craniofac Surg. 2021. https:\/\/doi.org\/10.7181\/acfs.2021.00003.","journal-title":"Arch Craniofac Surg"},{"key":"6141_CR129","first-page":"333","volume":"99","author":"H Purohit","year":"2020","unstructured":"Purohit H, Pisulkar SK, Mistry R, Dahihandekar C, Godbole S, Aswale S. Botox therapy beyond beauty. Int J Res Pharm Sci. 2020;99:333.","journal-title":"Int J Res Pharm Sci"},{"key":"6141_CR130","doi-asserted-by":"publisher","unstructured":"Fernandes de Sousa S, Caroline de Souza A, Silva Oliveira G, Braga Rolim Vieira R. Use of Botulinum toxin type A (Botox) and its aesthetic benefits. Health Soc. 2023;3(6). https:\/\/doi.org\/10.51249\/hs.v3i06.1739","DOI":"10.51249\/hs.v3i06.1739"},{"key":"6141_CR131","doi-asserted-by":"publisher","DOI":"10.7860\/JCDR\/2014\/11624.5341","author":"P Nayyar","year":"2014","unstructured":"Nayyar P, Kumar P, Nayyar PV, Singh A. Botox: broadening the horizon of dentistry. J Clin Diagn Res. 2014. https:\/\/doi.org\/10.7860\/JCDR\/2014\/11624.5341.","journal-title":"J Clin Diagn Res"},{"key":"6141_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.cden.2020.06.003","author":"P Tran Cao","year":"2020","unstructured":"Tran Cao P. The use of Botulinum toxin and dermal fillers to enhance patients\u2019 perceived attractiveness: implications for the future of aesthetic dentistry. Dent Clin N Am. 2020. https:\/\/doi.org\/10.1016\/j.cden.2020.06.003.","journal-title":"Dent Clin N Am"},{"key":"6141_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2016.04.024","author":"KH Awan","year":"2017","unstructured":"Awan KH. The therapeutic usage of Botulinum toxin (Botox) in non-cosmetic head and neck conditions\u2014an evidence based review. Saudi Pharm J. 2017. https:\/\/doi.org\/10.1016\/j.jsps.2016.04.024.","journal-title":"Saudi Pharm J"},{"key":"6141_CR134","doi-asserted-by":"publisher","DOI":"10.9734\/jpri\/2020\/v32i1530623","author":"NAAB Zaaba","year":"2020","unstructured":"Zaaba NAAB, Ganapathy D, Duraisamy R. Awareness of Botox injections in facial aesthetics among dental students. J Pharm Res Int. 2020. https:\/\/doi.org\/10.9734\/jpri\/2020\/v32i1530623.","journal-title":"J Pharm Res Int"},{"key":"6141_CR135","doi-asserted-by":"publisher","DOI":"10.1215\/00382876-105-1-71","author":"GC Singh","year":"2006","unstructured":"Singh GC, Hankins MC, Dulku A, Kelly MBH. Psychosocial aspects of Botox in aesthetic surgery. Aesthet Plast Surg. 2006. https:\/\/doi.org\/10.1215\/00382876-105-1-71.","journal-title":"Aesthet Plast Surg"},{"key":"6141_CR136","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2618-11.2011","author":"L Restani","year":"2011","unstructured":"Restani L, Antonucci F, Gianfranceschi L, Rossi C, Rossetto O, Caleo M. Evidence for anterograde transport and transcytosis of Botulinum neurotoxin A (BoNT\/A). J Neurosci. 2011. https:\/\/doi.org\/10.1523\/JNEUROSCI.2618-11.2011.","journal-title":"J Neurosci"},{"key":"6141_CR137","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2012.05.001","author":"I Matak","year":"2012","unstructured":"Matak I, Riederer P, Lackovi\u0107 Z. Botulinum toxin\u2019s axonal transport from periphery to the spinal cord. Neurochem Int. 2012. https:\/\/doi.org\/10.1016\/j.neuint.2012.05.001.","journal-title":"Neurochem Int"},{"key":"6141_CR138","doi-asserted-by":"publisher","DOI":"10.3344\/kjp.2022.35.4.391","author":"H Bu","year":"2022","unstructured":"Bu H, Jiao P, Fan X, Gao Y, Zhang L, Guo H. The role of Botulinum toxin type A related axon transport in neuropathic pain induced by chronic constriction injury. Korean J Pain. 2022. https:\/\/doi.org\/10.3344\/kjp.2022.35.4.391.","journal-title":"Korean J Pain"},{"key":"6141_CR139","doi-asserted-by":"publisher","DOI":"10.3390\/toxins13100704","author":"A Waskitho","year":"2021","unstructured":"Waskitho A, Yamamoto Y, Raman S, Kano F, Yan H, Raju R, et al. Peripherally administered Botulinum toxin type a localizes bilaterally in trigeminal ganglia of animal model. Toxins. 2021. https:\/\/doi.org\/10.3390\/toxins13100704.","journal-title":"Toxins"},{"key":"6141_CR140","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000174433.76707.8c","author":"R Tintner","year":"2005","unstructured":"Tintner R, Gross R, Winzer UF, Smalky KA, Jankovic J. Autonomic function after Botulinum toxin type A or B: a double-blind randomized trial. Neurology. 2005. https:\/\/doi.org\/10.1212\/01.wnl.0000174433.76707.8c.","journal-title":"Neurology"},{"key":"6141_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2018.08.021","author":"NH Waldron","year":"2019","unstructured":"Waldron NH, Cooter M, Haney JC, Schroder JN, Gaca JG, Lin SS, et al. Temporary autonomic modulation with Botulinum toxin type A to reduce atrial fibrillation after cardiac surgery. Heart Rhythm. 2019. https:\/\/doi.org\/10.1016\/j.hrthm.2018.08.021.","journal-title":"Heart Rhythm"},{"key":"6141_CR142","doi-asserted-by":"publisher","DOI":"10.1007\/s11062-015-9540-z","author":"M Galazka","year":"2015","unstructured":"Galazka M, Soszynski D, Dmitruk K. Central action of Botulinum toxin type A\u2014Is it possible? Neurophysiology. 2015. https:\/\/doi.org\/10.1007\/s11062-015-9540-z.","journal-title":"Neurophysiology"},{"issue":"8","key":"6141_CR143","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3390\/toxins17080396","volume":"17","author":"M Dudzic","year":"2025","unstructured":"Dudzic M, Pieczy\u0144ska A, Dru\u017cd\u017c A, Rajewska A, Hojan K. Is there a \u2018non-motor effect\u2019 of Botulinum toxin treatment in cervical dystonia in addition to its effects on motor symptoms? Toxins. 2025;17(8):396. https:\/\/doi.org\/10.3390\/toxins17080396.","journal-title":"Toxins"},{"key":"6141_CR144","doi-asserted-by":"publisher","DOI":"10.3390\/toxins13020120","author":"E Martina","year":"2021","unstructured":"Martina E, Diotallevi F, Radi G, Campanati A, Offidani A. Therapeutic use of Botulinum neurotoxins in dermatology: systematic review. Toxins. 2021. https:\/\/doi.org\/10.3390\/toxins13020120.","journal-title":"Toxins"},{"key":"6141_CR145","doi-asserted-by":"publisher","DOI":"10.1007\/s10354-017-0553-7","author":"K Fran\u00e7a","year":"2017","unstructured":"Fran\u00e7a K, Kumar A, Fioranelli M, Lotti T, Tirant M, Roccia MG. The history of Botulinum toxin: from poison to beauty. Wien Med Wochenschr. 2017. https:\/\/doi.org\/10.1007\/s10354-017-0553-7.","journal-title":"Wien Med Wochenschr"},{"key":"6141_CR146","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2147\/CCID.S160723","volume":"11","author":"J Frevert","year":"2018","unstructured":"Frevert J, Ahn KY, Park MY, Sunga O. Comparison of Botulinum neurotoxin type A formulations in Asia. Clin Cosmet Investig Dermatol. 2018;11:327\u201331. https:\/\/doi.org\/10.2147\/CCID.S160723.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"50","key":"6141_CR147","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1097\/DSS.0000000000004284","volume":"9","author":"R Avelar","year":"2024","unstructured":"Avelar R. Botulinum toxin accessory proteins: Are they just an accessory? Dermatol Surg. 2024;9(50):S38\u201341. https:\/\/doi.org\/10.1097\/DSS.0000000000004284.","journal-title":"Dermatol Surg"},{"issue":"s1","key":"6141_CR148","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1468-1331.2006.01438.x","volume":"13","author":"RL Rosales","year":"2006","unstructured":"Rosales RL, Bigalke H, Dressler D. Pharmacology of Botulinum toxin: differences between type A preparations. Eur J Neurol. 2006;13(s1):2\u201310. https:\/\/doi.org\/10.1111\/j.1468-1331.2006.01438.x.","journal-title":"Eur J Neurol"},{"key":"6141_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2022.05.028","author":"Z Mari","year":"2022","unstructured":"Mari Z. Diffusion, spread, and migration of Botulinum toxin: an update. Toxicon. 2022. https:\/\/doi.org\/10.1016\/j.toxicon.2022.05.028.","journal-title":"Toxicon"},{"key":"6141_CR150","unstructured":"Dowson C, Sahai A, Smith J, Khan MS, Dasgupta P. Poison to prescription: a history of Botulinum toxin in medicine. BJU Int. 2009."},{"key":"6141_CR151","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-007-0728-2","author":"FJ Erbguth","year":"2008","unstructured":"Erbguth FJ. From poison to remedy: the chequered history of Botulinum toxin. J Neural Trans. 2008. https:\/\/doi.org\/10.1007\/s00702-007-0728-2.","journal-title":"J Neural Trans"},{"key":"6141_CR152","doi-asserted-by":"publisher","DOI":"10.1089\/fpsam.2023.0198","author":"SJ Torabi","year":"2024","unstructured":"Torabi SJ, Vasudev M, Lonergan A, Hsu TI, Dalwadi PP, Wong BJF, et al. Trends in Botulinum toxin-related industry payments to physicians. Facial Plast Surg Aesthet Med. 2024. https:\/\/doi.org\/10.1089\/fpsam.2023.0198.","journal-title":"Facial Plast Surg Aesthet Med"},{"key":"6141_CR153","doi-asserted-by":"publisher","DOI":"10.12968\/joan.2018.7.5.240","author":"S Patel","year":"2018","unstructured":"Patel S. Post-treatment advice following Botulinum toxin injections: a review. J Aesthet Nurs. 2018. https:\/\/doi.org\/10.12968\/joan.2018.7.5.240.","journal-title":"J Aesthet Nurs"},{"key":"6141_CR154","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8635(03)00018-4","author":"AM Mantell","year":"2004","unstructured":"Mantell AM. Dilution, storage, and electromyographic guidance in the use of Botulinum toxins. Dermatol Clin. 2004. https:\/\/doi.org\/10.1016\/S0733-8635(03)00018-4.","journal-title":"Dermatol Clin"},{"key":"6141_CR155","doi-asserted-by":"publisher","DOI":"10.1177\/1073858414524633","author":"R Mazzocchio","year":"2015","unstructured":"Mazzocchio R, Caleo M. More than at the neuromuscular synapse: actions of botulinum neurotoxin A in the central nervous system. Neuroscientist. 2015. https:\/\/doi.org\/10.1177\/1073858414524633.","journal-title":"Neuroscientist"},{"key":"6141_CR156","doi-asserted-by":"publisher","DOI":"10.3390\/toxins14050329","author":"NK Rho","year":"2022","unstructured":"Rho NK, Han KH, Kim HS. An update on the cosmetic use of Botulinum toxin: the pattern of practice among Korean dermatologists. Toxins. 2022. https:\/\/doi.org\/10.3390\/toxins14050329.","journal-title":"Toxins"},{"key":"6141_CR157","doi-asserted-by":"publisher","DOI":"10.2165\/11592100-000000000-00000","author":"LA Dessy","year":"2011","unstructured":"Dessy LA, Fallico N, Mazzocchi M, Scuderi N. Botulinum toxin for glabellar lines: a review of the efficacy and safety of currently available products. Am J Clin Dermatol. 2011. https:\/\/doi.org\/10.2165\/11592100-000000000-00000.","journal-title":"Am J Clin Dermatol"},{"issue":"9S","key":"6141_CR158","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1097\/DSS.0000000000004293","volume":"50","author":"E Rahman","year":"2024","unstructured":"Rahman E, Carruthers JDA. Immunogenicity of Botulinum toxin A: insights. Dermatol Surg. 2024;50(9S):S117\u201326. https:\/\/doi.org\/10.1097\/DSS.0000000000004293.","journal-title":"Dermatol Surg"},{"key":"6141_CR159","doi-asserted-by":"publisher","DOI":"10.1055\/a-1730-8270","author":"WG Philipp-Dormston","year":"2022","unstructured":"Philipp-Dormston WG, Bertossi D, Houschyar K, Rahman E. Botulinum toxins for esthetic facial injections: a scientific review to support evidence-based best practice. Facial Plast Surg. 2022. https:\/\/doi.org\/10.1055\/a-1730-8270.","journal-title":"Facial Plast Surg"},{"issue":"1","key":"6141_CR160","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s00238-024-02252-8","volume":"47","author":"WR Webb","year":"2024","unstructured":"Webb WR, Rao P, Garcia PE, Carruthers JDA, Rahman E. Harmony and hype: navigating translational science in aesthetic medicine and plastic surgery. Eur J Plast Surg. 2024;47(1):104. https:\/\/doi.org\/10.1007\/s00238-024-02252-8.","journal-title":"Eur J Plast Surg"},{"issue":"1","key":"6141_CR161","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s00238-025-02311-8","volume":"48","author":"E Rahman","year":"2025","unstructured":"Rahman E, Peter Peng H-L, Wu WTL, Webb WR. In silico multiscale comparison of LetibotulinumtoxinA and OnabotulinumtoxinA in glabellar line treatment: diffusion dynamics, receptor affinity, and immunologic clearance. Eur J Plast Surg. 2025;48(1):52. https:\/\/doi.org\/10.1007\/s00238-025-02311-8.","journal-title":"Eur J Plast Surg"},{"key":"6141_CR162","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2025.108560","volume":"267","author":"E Rahman","year":"2025","unstructured":"Rahman E, DA Carruthers J, Ahmed M, Flanagan A, Peng H-LP, Goodman GJ, et al. Targeting the glabellar frown lines with OnabotulinumtoxinA: in-silico evidence supporting concentrated, low-volume injection protocols. Toxicon. 2025;267:108560. https:\/\/doi.org\/10.1016\/j.toxicon.2025.108560.","journal-title":"Toxicon"},{"key":"6141_CR163","doi-asserted-by":"publisher","DOI":"10.1007\/s00266-024-04016-y","author":"E Rahman","year":"2024","unstructured":"Rahman E, Webb WR, Rao P, Yu N, Garcia PE, Ioannidis S, et al. A systematic review on the reinforcement loop in aesthetic medicine and surgery: the interplay of social media, self-perception, and repeat procedures. Aesthet Plast Surg. 2024. https:\/\/doi.org\/10.1007\/s00266-024-04016-y.","journal-title":"Aesthet Plast Surg"},{"issue":"8","key":"6141_CR164","doi-asserted-by":"publisher","DOI":"10.1097\/GOX.0000000000006084","volume":"12","author":"E Rahman","year":"2024","unstructured":"Rahman E, Rao P, Philipp-Dormston W, Webb WR, Garcia PE, Ioannidis S, et al. Intradermal Botulinum toxin A on skin quality and facial rejuvenation: a systematic review and meta-analysis. Plast Reconstr Surg Glob Open. 2024;12(8):e6084. https:\/\/doi.org\/10.1097\/GOX.0000000000006084.","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"6141_CR165","doi-asserted-by":"publisher","DOI":"10.1037\/a0018690","author":"JI Davis","year":"2010","unstructured":"Davis JI, Senghas A, Brandt F, Ochsner KN. The effects of Botox injections on emotional experience. Emotion. 2010. https:\/\/doi.org\/10.1037\/a0018690.","journal-title":"Emotion"},{"key":"6141_CR166","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijom.2016.11.004","author":"ST Connelly","year":"2017","unstructured":"Connelly ST, Myung J, Gupta R, Tartaglia GM, Gizdulich A, Yang J, et al. Clinical outcomes of Botox injections for chronic temporomandibular disorders: Do we understand how Botox works on muscle, pain, and the brain? Int J Oral Maxillofac Surg. 2017. https:\/\/doi.org\/10.1016\/j.ijom.2016.11.004.","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"1","key":"6141_CR167","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1177\/201010581202100106","volume":"21","author":"L Teo","year":"2012","unstructured":"Teo L, Chee E. Uses of Botulinum toxin A in ophthalmology. Proc Singap Healthc. 2012;21(1):30\u20139. https:\/\/doi.org\/10.1177\/201010581202100106.","journal-title":"Proc Singap Healthc"},{"key":"6141_CR168","doi-asserted-by":"publisher","DOI":"10.9734\/ajmah\/2023\/v21i11954","author":"J Mukherjee","year":"2023","unstructured":"Mukherjee J, Naresh V, Krishna AS, Boggula N, Rao TR. Botox treatment: a comprehensive review. Asian J Med Health. 2023. https:\/\/doi.org\/10.9734\/ajmah\/2023\/v21i11954.","journal-title":"Asian J Med Health"},{"key":"6141_CR169","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032371","author":"AB Scott","year":"2023","unstructured":"Scott AB, Honeychurch D, Brin MF. Early development history of Botox (OnabotulinumtoxinA). Medicine (U S). 2023. https:\/\/doi.org\/10.1097\/MD.0000000000032371.","journal-title":"Medicine (U S)"},{"issue":"4","key":"6141_CR170","doi-asserted-by":"publisher","first-page":"e4217","DOI":"10.1097\/GOX.0000000000004217","volume":"10","author":"J-Y Park","year":"2022","unstructured":"Park J-Y, Corduff N, Frevert J, Wanitphakdeedecha R, Chao YYY. Immunogenicity associated with aesthetic Botulinumtoxin A: a survey of Asia-Pacific physicians\u2019 experiences and recommendations. Plast Reconstr Surg Glob Open. 2022;10(4):e4217.","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"6141_CR171","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2009.04071.x","author":"M Kawashima","year":"2009","unstructured":"Kawashima M, Harii K. An open-label, randomized, 64-week study repeating 10- and 20-U doses of Botulinum toxin type A for treatment of glabellar lines in Japanese subjects. Int J Dermatol. 2009. https:\/\/doi.org\/10.1111\/j.1365-4632.2009.04071.x.","journal-title":"Int J Dermatol"},{"key":"6141_CR172","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2006.32332.x","author":"G Monheit","year":"2007","unstructured":"Monheit G, Carruthers A, Brandt F, Rand R. A randomized, double-blind, placebo-controlled study of Botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg. 2007. https:\/\/doi.org\/10.1111\/j.1524-4725.2006.32332.x.","journal-title":"Dermatol Surg"},{"key":"6141_CR173","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.70508","author":"AGM Hopf","year":"2025","unstructured":"Hopf AGM, Buchheim A, Hopf M, Cajkovsk\u00fd M, Eilert DW. A psychological guide to upper face Botulinum toxin injections: baseline emotional functions of facial expressions. J Cosmet Dermatol. 2025. https:\/\/doi.org\/10.1111\/jocd.70508.","journal-title":"J Cosmet Dermatol"},{"key":"6141_CR174","doi-asserted-by":"publisher","DOI":"10.2196\/69960","author":"G Kroumpouzos","year":"2025","unstructured":"Kroumpouzos G, Silikovich F. Exploring nonresponse to Botulinum toxin in aesthetics: narrative review of key trigger factors and effective management strategies. JMIR Dermatol. 2025. https:\/\/doi.org\/10.2196\/69960.","journal-title":"JMIR Dermatol"},{"key":"6141_CR175","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2024.107385","author":"A Curry","year":"2024","unstructured":"Curry A. Awareness of aesthetic and therapeutic crossover usage of Botulinum neurotoxin type A. Toxicon. 2024. https:\/\/doi.org\/10.1016\/j.toxicon.2024.107385.","journal-title":"Toxicon"},{"key":"6141_CR176","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000003192","author":"J Zajac","year":"2021","unstructured":"Zajac J, Chandawarkar A, Sherber N. #Botox 101: subgroup analysis of Twitter\u2019s top 101 neurotoxin influencers. Dermatol Surg. 2021. https:\/\/doi.org\/10.1097\/DSS.0000000000003192.","journal-title":"Dermatol Surg"},{"issue":"13","key":"6141_CR177","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1002\/mds.25582","volume":"28","author":"J Ramirez-Castaneda","year":"2013","unstructured":"Ramirez-Castaneda J, Jankovic J, Comella C, Dashtipour K, Fernandez HH, Mari Z. Diffusion, spread, and migration of Botulinum toxin. Mov Disord. 2013;28(13):1775\u201383. https:\/\/doi.org\/10.1002\/mds.25582.","journal-title":"Mov Disord"},{"key":"6141_CR178","doi-asserted-by":"publisher","DOI":"10.1097\/01.nt.0000324694.11231.38","author":"J Talan","year":"2008","unstructured":"Talan J. Study finds Botulinum toxin spreads to CNS tissue in mice. Neurol Today. 2008. https:\/\/doi.org\/10.1097\/01.nt.0000324694.11231.38.","journal-title":"Neurol Today"},{"issue":"2","key":"6141_CR179","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00403-011-1179-z","volume":"304","author":"M Kerscher","year":"2012","unstructured":"Kerscher M, Roll S, Becker A, Wigger-Alberti W. Comparison of the spread of three Botulinum toxin type A preparations. Arch Dermatol Res. 2012;304(2):155\u201361. https:\/\/doi.org\/10.1007\/s00403-011-1179-z.","journal-title":"Arch Dermatol Res"},{"issue":"8","key":"6141_CR180","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/asj\/sjad038","volume":"43","author":"R Siperstein","year":"2023","unstructured":"Siperstein R. Review of Botulinum toxin uptake and novel theory regarding potential spread days after injection. Aesthetic Surg J. 2023;43(8):887\u201392. https:\/\/doi.org\/10.1093\/asj\/sjad038.","journal-title":"Aesthetic Surg J"},{"key":"6141_CR181","doi-asserted-by":"publisher","DOI":"10.1007\/s00266-021-02483-1","author":"A Borba","year":"2022","unstructured":"Borba A, Matayoshi S, Rodrigues M. Avoiding complications on the upper face treatment with Botulinum toxin: a practical guide. Aesthet Plast Surg. 2022. https:\/\/doi.org\/10.1007\/s00266-021-02483-1.","journal-title":"Aesthet Plast Surg"},{"key":"6141_CR182","doi-asserted-by":"publisher","DOI":"10.1016\/j.fsc.2013.02.009","author":"M Loyo","year":"2013","unstructured":"Loyo M, Kontis TC. Cosmetic Botulinum toxin: has it replaced more invasive facial procedures? Facial Plast Surg Clin N Am. 2013. https:\/\/doi.org\/10.1016\/j.fsc.2013.02.009.","journal-title":"Facial Plast Surg Clin N Am"},{"key":"6141_CR183","doi-asserted-by":"publisher","DOI":"10.1111\/joor.13590","author":"MS Moussa","year":"2024","unstructured":"Moussa MS, Bachour D, Komarova SV. Adverse effect of Botulinum toxin-A injections on mandibular bone: a systematic review and meta-analysis. J Oral Rehabil. 2024. https:\/\/doi.org\/10.1111\/joor.13590.","journal-title":"J Oral Rehabil"},{"key":"6141_CR184","doi-asserted-by":"publisher","DOI":"10.3390\/toxins10090374","author":"C Rasetti-Escargueil","year":"2018","unstructured":"Rasetti-Escargueil C, Lemichez E, Popoff MR. Variability of Botulinum toxins: challenges and opportunities for the future. Toxins. 2018. https:\/\/doi.org\/10.3390\/toxins10090374.","journal-title":"Toxins"},{"key":"6141_CR185","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e31826248b8","author":"M Ghasemi","year":"2012","unstructured":"Ghasemi M, Norouzi R, Salari M, Asadi B. Iatrogenic Botulism after the therapeutic use of Botulinum toxin-A: a case report and review of the literature. Clin Neuropharm. 2012. https:\/\/doi.org\/10.1097\/WNF.0b013e31826248b8.","journal-title":"Clin Neuropharm"},{"key":"6141_CR186","doi-asserted-by":"publisher","DOI":"10.1177\/0956797610374742","author":"DA Havas","year":"2010","unstructured":"Havas DA, Glenberg AM, Gutowski KA, Lucarelli MJ, Davidson RJ. Cosmetic use of Botulinum toxin-A affects processing of emotional language. Psychol Sci. 2010. https:\/\/doi.org\/10.1177\/0956797610374742.","journal-title":"Psychol Sci"},{"key":"6141_CR187","doi-asserted-by":"publisher","unstructured":"Brodsky MA, Swope DM, Grimes D. Diffusion of Botulinum toxins. Tremor and Other Hyperkinetic Movements. 2012;2:tre-02-85-417-1. https:\/\/doi.org\/10.7916\/D88W3C1M","DOI":"10.7916\/D88W3C1M"},{"issue":"5","key":"6141_CR188","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/mdc3.12322","volume":"3","author":"H Hefter","year":"2016","unstructured":"Hefter H, Rosenthal D, Moll M. High Botulinum toxin-neutralizing antibody prevalence under long-term cervical dystonia treatment. Mov Disord Clin Pract. 2016;3(5):500\u20136. https:\/\/doi.org\/10.1002\/mdc3.12322.","journal-title":"Mov Disord Clin Pract"},{"key":"6141_CR189","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2008.04.054","author":"P Andy","year":"2008","unstructured":"Andy P, Martin M. Counterfeit Botulinum toxins\u2014a serious risk to patient safety. Toxicon. 2008. https:\/\/doi.org\/10.1016\/j.toxicon.2008.04.054.","journal-title":"Toxicon"},{"key":"6141_CR190","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2011.02087.x","author":"AR Trindade De Almeida","year":"2011","unstructured":"Trindade De Almeida AR, Secco LC, Carruthers A. Handling Botulinum toxins: an updated literature review. Dermatol Surg. 2011. https:\/\/doi.org\/10.1111\/j.1524-4725.2011.02087.x.","journal-title":"Dermatol Surg"},{"issue":"3","key":"6141_CR191","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0031-6997(25)06852-8","volume":"33","author":"LL Simpson","year":"1981","unstructured":"Simpson LL. The origin, structure, and pharmacological activity of Botulinum toxin. Pharmacol Rev. 1981;33(3):155\u201388.","journal-title":"Pharmacol Rev"},{"key":"6141_CR192","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0b013e318170813c","author":"AW Klein","year":"2008","unstructured":"Klein AW, Carruthers A, Fagien S, Lowe NJ. Comparsisons among Botulinum toxins: an evidence-based review. Plast Reconstr Surg. 2008. https:\/\/doi.org\/10.1097\/PRS.0b013e318170813c.","journal-title":"Plast Reconstr Surg"},{"issue":"4","key":"6141_CR193","doi-asserted-by":"publisher","first-page":"e413691","DOI":"10.1111\/srt.13691","volume":"30","author":"SM Oh","year":"2024","unstructured":"Oh SM, Kim HM, Ahn TH, Park MS, Ree Y-S, Park ES. Aesthetic doctors\u2019 perception and attitudes toward tolerance in Botulinum toxin. Skin Res Technol. 2024;30(4):e413691. https:\/\/doi.org\/10.1111\/srt.13691.","journal-title":"Skin Res Technol"},{"key":"6141_CR194","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.70264","author":"RJ Vanaria","year":"2025","unstructured":"Vanaria RJ, Chaudry A, Marrero-Perez AC, Lorenc ZP, Nestor MS. The face of emotion: Botulinum toxin, emotional anatomy, and mood modulation. J Cosmet Dermatol. 2025. https:\/\/doi.org\/10.1111\/jocd.70264.","journal-title":"J Cosmet Dermatol"},{"issue":"5","key":"6141_CR195","doi-asserted-by":"publisher","first-page":"489","DOI":"10.4103\/IJMR.2010_132_05_489","volume":"132","author":"RK Dhaked","year":"2010","unstructured":"Dhaked RK, Singh MK, Singh P, Gupta P. Botulinum toxin: bioweapon & magic drug. Indian J Med Res. 2010;132(5):489\u2013503.","journal-title":"Indian J Med Res"},{"issue":"8","key":"6141_CR196","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/mds.27072","volume":"32","author":"J Jankovic","year":"2017","unstructured":"Jankovic J. Botulinum toxin: state of the art. Mov Disord. 2017;32(8):1131\u20138. https:\/\/doi.org\/10.1002\/mds.27072.","journal-title":"Mov Disord"},{"key":"6141_CR197","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2017.11.010","author":"Z Lackovic","year":"2018","unstructured":"Lackovic Z, Bach-Rojecky L, Drinovac Vlah V. Botulinum toxin: central or peripheral mechanism of action? Parkinsonism Relat Disord. 2018. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.11.010.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"6141_CR198","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3390\/toxins13010058","volume":"13","author":"S Choudhury","year":"2021","unstructured":"Choudhury S, Baker MR, Chatterjee S, Kumar H. Botulinum toxin: an update on pharmacology and newer products in development. Toxins. 2021;13(1):58. https:\/\/doi.org\/10.3390\/toxins13010058.","journal-title":"Toxins"},{"key":"6141_CR199","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2012.01.027","author":"MA Wollmer","year":"2012","unstructured":"Wollmer MA, De Boer C, Kalak N, Beck J, G\u00f6tz T, Schmidt T, et al. Facing depression with Botulinum toxin: a randomized controlled trial. J Psychiatr Res. 2012. https:\/\/doi.org\/10.1016\/j.jpsychires.2012.01.027.","journal-title":"J Psychiatr Res"},{"key":"6141_CR200","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-125-7-199610010-00013","author":"LL Simpson","year":"1996","unstructured":"Simpson LL. Botulinum toxin: a deadly poison sheds its negative image. Annals Intern Med. 1996. https:\/\/doi.org\/10.7326\/0003-4819-125-7-199610010-00013.","journal-title":"Annals Intern Med"},{"key":"6141_CR201","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4914(03)00113-8","author":"PG Foran","year":"2003","unstructured":"Foran PG, Davletov B, Meunier FA. Getting muscles moving again after Botulinum toxin: novel therapeutic challenges. Trends Mol Med. 2003. https:\/\/doi.org\/10.1016\/S1471-4914(03)00113-8.","journal-title":"Trends Mol Med"},{"issue":"3","key":"6141_CR202","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1353\/pbm.1997.0032","volume":"40","author":"EJ Schantz","year":"1997","unstructured":"Schantz EJ, Johnson EA. Botulinum toxin: the story of its development for the treatment of human disease. Perspect Biol Med. 1997;40(3):317\u201327. https:\/\/doi.org\/10.1353\/pbm.1997.0032.","journal-title":"Perspect Biol Med"},{"key":"6141_CR203","doi-asserted-by":"publisher","DOI":"10.1016\/j.cps.2016.03.003","author":"MS Gart","year":"2016","unstructured":"Gart MS, Gutowski KA. Overview of Botulinum toxins for aesthetic uses. Clin Plast Surg. 2016. https:\/\/doi.org\/10.1016\/j.cps.2016.03.003.","journal-title":"Clin Plast Surg"},{"key":"6141_CR204","doi-asserted-by":"publisher","DOI":"10.3390\/toxins10080313","author":"M Salari","year":"2018","unstructured":"Salari M, Sharma S, Jog MS. Botulinum toxin induced atrophy: an uncharted territory. Toxins. 2018. https:\/\/doi.org\/10.3390\/toxins10080313.","journal-title":"Toxins"},{"key":"6141_CR205","doi-asserted-by":"publisher","DOI":"10.1002\/9781118661833.ch8","author":"M Alam","year":"2017","unstructured":"Alam M, Gladstone HB, Ozog DM. Reconstitution, dilution, diffusion, and migration of Botulinum toxin. Botulinum Toxins Cosmet Clin Appl. 2017. https:\/\/doi.org\/10.1002\/9781118661833.ch8.","journal-title":"Botulinum Toxins Cosmet Clin Appl"},{"key":"6141_CR206","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S363321","author":"V Shtefan","year":"2022","unstructured":"Shtefan V, Fletcher J, Duclos OA. Causes of Botulinum toxin treatment failure. Clin Cosmet Investig Dermatol. 2022. https:\/\/doi.org\/10.2147\/CCID.S363321.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"2","key":"6141_CR207","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/PRA.0000000000000136","volume":"22","author":"AK Parsaik","year":"2016","unstructured":"Parsaik AK, Mascarenhas SS, Hashmi A, Prokop LJ, John V, Okusaga O, et al. Role of Botulinum toxin in depression. J Psychiatr Pract. 2016;22(2):99\u2013110. https:\/\/doi.org\/10.1097\/PRA.0000000000000136.","journal-title":"J Psychiatr Pract"},{"key":"6141_CR208","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2020.02.008","author":"Z Lackovi\u0107","year":"2020","unstructured":"Lackovi\u0107 Z. New analgesic: focus on Botulinum toxin. Toxicon. 2020. https:\/\/doi.org\/10.1016\/j.toxicon.2020.02.008.","journal-title":"Toxicon"},{"key":"6141_CR209","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2024.107492","author":"N Solish","year":"2024","unstructured":"Solish N, Moradi A, Shridharani S, Donofrio L, Gold MH, Biesman B, et al. Treatment of moderate-to-severe glabellar lines with RelabotulinumtoxinA an investigational liquid Botulinum toxin: clinical efficacy and safety results from the READY-1 phase 3 trial. Toxicon. 2024. https:\/\/doi.org\/10.1016\/j.toxicon.2024.107492.","journal-title":"Toxicon"},{"key":"6141_CR210","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.265","author":"D Zargaran","year":"2023","unstructured":"Zargaran D, Zargaran A, Sousi S, Knight D, Cook H, Woollard A, et al. Quantitative and qualitative analysis of individual experiences post Botulinum toxin injection\u2014United Kingdom survey. Skin Health Dis. 2023. https:\/\/doi.org\/10.1002\/ski2.265.","journal-title":"Skin Health Dis"},{"key":"6141_CR211","unstructured":"What are the bad effects of Botox? Quora. https:\/\/www.quora.com\/What-are-the-bad-effects-of-Botox. Retrieved 5 October 2025."},{"issue":"3","key":"6141_CR212","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1037\/a0018690","volume":"10","author":"J Ian Davis","year":"2010","unstructured":"Ian Davis J, Senghas A, Brandt F, Kevin Ochsner NN. The effects of BOTOX\u00ae injections on emotional experience and private practice in coral gables. Emotion. 2010;10(3):433.","journal-title":"Emotion"},{"key":"6141_CR213","doi-asserted-by":"publisher","DOI":"10.3366\/soma.2021.0338","author":"SR Rasmussen","year":"2021","unstructured":"Rasmussen SR. \u2018Men dont do Botox, they do Brotox\u2019\u2014emerging configurations of masculinity in the marketing of cosmetic treatments online. Somatechnics. 2021. https:\/\/doi.org\/10.3366\/soma.2021.0338.","journal-title":"Somatechnics"},{"key":"6141_CR214","doi-asserted-by":"publisher","DOI":"10.1111\/dsu.12097","author":"AE Rose","year":"2013","unstructured":"Rose AE, Goldberg DJ. Safety and efficacy of intradermal injection of Botulinum toxin for the treatment of oily skin. Dermatol Surg. 2013. https:\/\/doi.org\/10.1111\/dsu.12097.","journal-title":"Dermatol Surg"},{"key":"6141_CR215","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2010.01703.x","author":"R Kapoor","year":"2010","unstructured":"Kapoor R, Shome D, Jain V, Dikshit R. Facial rejuvenation after intradermal Botulinum toxin: Is it really the Botulinum toxin or is it the pricks? Dermatol Surg. 2010. https:\/\/doi.org\/10.1111\/j.1524-4725.2010.01703.x.","journal-title":"Dermatol Surg"}],"container-title":["Aesthetic Plastic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00266-026-06141-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00266-026-06141-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00266-026-06141-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:52:13Z","timestamp":1791388333000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00266-026-06141-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":215,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["6141"],"URL":"https:\/\/doi.org\/10.1007\/s00266-026-06141-2","relation":{},"ISSN":["0364-216X","1432-5241"],"issn-type":[{"value":"0364-216X","type":"print"},{"value":"1432-5241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest to disclose in relation to this manuscript. Karim Sayed is a consultant to, speaker for, and has received honoraria from L\u2019or\u00e9al\/Skinceuticals, Teoxane, Lutronic, Cynosure and Allergan, an AbbVie Company (Irvine, CA); Dr Nicoloso, Dr Sokratous, and Dr Shahsavar have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Human and Animal Rights","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For this type of study, informed consent is not required.","order":3,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}